🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase III

Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
1,266

Quick answer

Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 16 of 27

  1. Obinutuzumab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial

  2. Obinutuzumab

    United Therapeutics Europe Ltd

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    1 trial

  3. Ociperlimab, Ociperlimab, Pamiparib, Pamiparib, Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Solid tumors and hamatological malignancies

    phase 3 small molecule active

    1 trial

  4. Odronextamab

    Regeneron UK Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  5. Odronextamab

    ADC Therapeutics SA

    B-cell Non Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  6. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma (FL)

    phase 3 small molecule active

    2 trials

  7. Odronextamab

    Regeneron UK Limited

    Diffuse Large B-cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  8. Olaparib

    AstraZeneca

    Breast Cancer Metastatic

    phase 3 small molecule completed

    1 trial

  9. Olaparib 300mg tablets

    AstraZeneca

    Relapsed Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  10. Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  11. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  12. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  13. Opevesostat, FLUDROCORTISONE, PREDNISOLONE, DEXAMETHASONE ACETATE, HYDROCORTISONE, FLUDROCORTISONE ACETATE, ABIRATERONE ACETATE, DEXAMETHASONE, ABIRATERONE ACETATE, HYDROCORTISONE, HYDROCORTISONE, ENZALUTAMIDE, HYDROCORTISONE, PREDNISONE, PREDNISONE ACETATE, HYDROCORTISONE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  14. Oral immunonutrition

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 3 other active

    1 trial

  15. Orteronel

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  16. Osimertinib

    The First People's Hospital of Lianyungang

    Non-small Cell Carcinoma

    phase 3 small molecule active

    1 trial

  17. Osimertinib

    AstraZeneca

    Cancer

    phase 3 small molecule active

    1 trial

  18. Oxaliplatin

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  19. Oxaliplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  20. Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  21. Oxybutynin Chloride

    United Therapeutics Europe Ltd

    Breast Carcinoma

    phase 3 small molecule completed

    1 trial

  22. PACLITAXEL , BNT327, PEMETREXED , CARBOPLATIN , BNT327, PEMBROLIZUMAB

    BioNTech SE

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  23. PACLITAXEL , GEMCITABINE , CARBOPLATIN , BNT327, Abraxane 5 mg/ml powder for dispersion for infusion., ERIBULIN , BNT327 Placebo

    BioNTech SE

    First line triple-negative breast cancer (TNBC)

    phase 3 small molecule active

    1 trial

  24. PACLITAXEL , Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, GEMCITABINE, FOLINIC ACID, FLUOROURACIL

    CERO THERAPEUTICS HOLDINGS, INC.

    Metastatic pancreatic cancer

    phase 3 small molecule active

    1 trial

  25. PACLITAXEL , Trodelvy 200 mg powder for concentrate for solution for infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion

    Gilead Sciences Pty Limited

    Recurrent or Persistent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  26. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  27. PACLITAXEL, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Placebo to MK-7339 100 mg, Placebo to MK-7339 150 mg, Olaparib, PACLITAXEL ALBUMIN-BOUND

    Merck Sharp and Dohme

    Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  28. PACLITAXEL, CISPLATIN, CARBOPLATIN, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  29. PACLITAXEL, Cyramza 10 mg/ml concentrate for solution for infusion, DS-8201a, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion

    Daiichi Sankyo

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  30. PACLITAXEL, FLUOROURACIL, DOCETAXEL, EXEMESTANE, DOXORUBICIN, CYCLOPHOSPHAMIDE, EPIRUBICIN, LETROZOLE, TAMOXIFEN, ANASTROZOLE

    Ningbo Cancer Hospital

    patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®

    phase 3 small molecule active

    1 trial

  31. PACLITAXEL, GEMCITABINE HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, GEMCITABINE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous).

    phase 3 small molecule active

    1 trial

  32. PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL

    Ningbo Cancer Hospital

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  33. PACLITAXEL, MYCOPHENOLATE MOFETIL, Abraxane 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion., Rilvegostomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN, INFLIXIMAB

    AstraZeneca AB

    Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

    phase 3 small molecule active

    1 trial

  34. PACLITAXEL, PF-08634404, SODIUM CHLORIDE, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, CARBOPLATIN, PEMETREXED

    Pfizer Australia Pty Ltd

    LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    phase 3 small molecule active

    1 trial

  35. PACLITAXEL, Raludotatug Deruxtecan, TOPOTECAN, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Daiichi Sankyo

    Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer

    phase 3 small molecule active

    1 trial

  36. PACLITAXEL, TOPOTECAN HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion

    Incyte

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  37. PANITUMUMAB, CAPECITABINE, CAPECITABINE, DISODIUM LEVOFOLINATE, CALCIUM LEVOFOLINATE, FLUOROURACIL, NIVOLUMAB, TEMOZOLOMIDE, FOLINIC ACID, TRASTUZUMAB, TEMOZOLOMIDE, PERTUZUMAB, TEMOZOLOMIDE, OXALIPLATIN, IPILIMUMAB, IRINOTECAN

    Fondazione Telethon ETS

    Colon cancer

    phase 3 small molecule active

    1 trial

  38. PARACETAMOL , -, -, CARBOPLATIN , -, MK-2870, PEMETREXED

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  39. PD-0332991

    Pfizer

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  40. PEGFILGRASTIM , PACLITAXEL , DOXORUBICIN , Rinatabart Sesutecan, GEMCITABINE , TOPOTECAN

    Genmab A/S

    Platinum-resistant Ovarian Cancer

    phase 3 small molecule active

    1 trial

  41. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial

  42. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Squamous cell carcinoma of head and neck

    phase 3 small molecule active

    1 trial

  43. PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE

    Lacuna Pharma Pty Ltd

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  44. PEMBROLIZUMAB , BNT113

    BioNTech SE

    Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer

    phase 3 small molecule active

    1 trial

  45. PEMBROLIZUMAB , IMFINZI 50 mg/mL concentrate for solution for infusion., JZP598, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Jazz Pharmaceuticals Ireland Limited

    BTC - Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  46. PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  47. PEMBROLIZUMAB , Placebo to match ly, ENFORTUMAB VEDOTIN

    Eli Lilly Co.

    Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  48. PEMBROLIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN, INFLIXIMAB, PACLITAXEL, MYCOPHENOLATE MOFETIL, GEMCITABINE, Datopotamab deruxtecan, PACLITAXEL ALBUMIN-BOUND

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase III programs exist?

1,266 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.